Roles
- Professor
- Vice Chair, Global and Community Health
- Director, Gynecologic Oncology Fellowship Program
- Co-Lead, Gynecologic Oncology Site Disease Group
- Medical Co-Director for Research Operations, SCCC Survivorship Program
- Assistant Director of Community Outreach and Engagement, Sylvester Comprehensive Cancer Center
-
Biography
Dr. Schlumbrecht is a Professor in the Division of Gynecologic Oncology at the Sylvester Comprehensive Cancer Center in Miami, Florida. He serves as the Director for the Gynecologic Oncology Fellowship Program; Medical Co-Director for Research Operations, Cancer Survivorship Program; and the Co-Director of Cancer Control and Prevention for Gynecologic Oncology. He also serves as the Vice Chair of Global and Community Health in the Department of Obstetrics, Gynecology, and Reproductive Sciences.
A graduate of The University of Texas Medical School at Houston, Dr. Schlumbrecht completed an OB/GYN residency at The University of Texas-Southwestern Medical Center in Dallas and a Gynecologic Oncology fellowship at The University of Texas MD Anderson Cancer Center in Houston. He holds a Master of Public Health in Epidemiology from the University of Texas. His clinical care of patients is complemented by his ongoing research in education, global health, and health care disparities, with a specific interest in cancer prevention, early detection, and education in underserved populations. He is the international mentor for gynecologic oncology fellows in Nigeria and Bahamas, and works closely with global partners to facilitate comprehensive research in endometrial and hereditary cancers.
He is the recipient of the 2021 Sylvester Comprehensive Cancer Center Zubrod Award for Outstanding Teacher. He has published in numerous peer-reviewed journals, including Journal of Clinical Oncology, Clinical Cancer Research, Cancer, and Gynecologic Oncology. -
Education & Training
Education
Post Graduate Training
Licensures and Certifications
-
Honors & Awards
-
Research Interests
Working in women's healthcare in a catchment area of diverse communities highlights the disparities in diagnosis, epidemiology, and access among those in gynecologic malignancies. My research approaches focuses on the issue of disparities from a number of domains, including biologic/genetic, genomic (microbiome/metagenomics), individual and interpersonal behaviors, and population-level investigations. The intersectionality of these domains is crucial to understand this complex issue and ultimate drive changes in policy and practice that will directly benefit the patients we serve. -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.Professional Activities
Articles & News
Breaking Barriers to Cancer Clinical Trial Participation
25th Zubrod Memorial Lecture and Awards Ceremony Honors Scientific Excellence and the Next Generation of Cancer Researchers
Sylvester Comprehensive Cancer Center Launches Clinical Trial on Fasting for Endometrial Cancer
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 13 clinical trials.
-
To assess safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s) EC Dose Optimization Part only: To determine the optimal dose of E7386 in combination with lenvatinib in endometrial carcinoma (EC)
- Principal Investigator: Matthew Schlumbrecht
- Study Phase: Phase II
- Enrollment Status: Not Accepting
-
To further evaluate the efficacy of R-DXd treatment measured by PFSas assessed by the investigator
- Principal Investigator: Matthew Schlumbrecht
- Study Phase: Phase II
- Enrollment Status: Not Accepting
-
To evaluate the antitumor activity of disitamab vedotin in subjects with previously treated, locally-advanced unresectable or metastatic (LA/m) HER2 expressing solid tumors. To evaluate the safety and tolerability profile of disitamab vedotin
- Principal Investigator: Matthew Schlumbrecht
- Study Phase: Phase II
- Enrollment Status: Closed
-
The current standard of care (SOC) for the treatment of ovarian cancer is a combination of chemotherapy (infusion of a platinum and /or a taxane) and surgery followed by chemotherapy (infusion of a platinum and /or a taxane) with or without bevacizumab.This research study is being done to evaluate if the ‘’investigational’' drug niraparib will help women with newly diagnosed ovarian cancer.
- Principal Investigator: Matthew Schlumbrecht
- Study Phase: Phase II
- Enrollment Status: Closed
-
To assess the safety of abemaciclib plus olaparib in patients with platinum-resistant ovarian cancer by determining the maximum tolerated dose and recommended phase 2 dose.
- Principal Investigator: Matthew Schlumbrecht
- Study Phase: Phase I
- Enrollment Status: Closed
-
Prospective, Single-Arm, Multicenter Study Evaluating Safety, Tolerability, and Metabolism of Niraparib as Maintenance following Front-Line Treatment for Ovarian Cancer in Women of African Ancestry
- Principal Investigator: Matthew Schlumbrecht
- Study Phase: Phase IV
- Enrollment Status: Open
-
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
- Principal Investigator: Matthew Schlumbrecht
- Study Phase: Phase 3
- Enrollment Status: Closed
-
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
- Principal Investigator: Matthew Schlumbrecht
- Study Phase: Phase 1/Phase 2
- Enrollment Status: Closed
-
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
- Principal Investigator: Matthew Schlumbrecht
- Study Phase: N/A
- Enrollment Status: Open
-
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
- Principal Investigator: Matthew Schlumbrecht
- Study Phase: N/A
- Enrollment Status: Open
-
To evaluate BICR-assessed ORR at each dose level of R-DXd
- Principal Investigator: Matthew Schlumbrecht
- Study Phase: Phase II/III
- Enrollment Status: Open
-
The purpose of this study is to help find out if neratinib with palbociclib is better than neratinib alone. To decide if it is better, the study doctors will be looking to see if the combination of neratinib and palbociclib will prevent cancer progression time compared to neratinib alone.
- Principal Investigator: Matthew Schlumbrecht
- Study Phase: Phase II
- Enrollment Status: Open
-
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
- Principal Investigator: Matthew Schlumbrecht
- Study Phase: Phase 3
- Enrollment Status: Closed
